Professor
Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University
Maastricht, Netherlands
Tilman Hackeng is director of Maastricht University’s Cardiovascular Research Institute (CARIM). Tilman Hackeng studied biochemistry at the University of Utrecht, where he obtained his PhD in 1993. He then became a postdoctoral fellow and senior researcher at The Scripps Research Institute in the USA before returning to the Netherlands as a Royal Netherlands Academy of Arts and Sciences Fellow at Maastricht University in 1998.
He is professor and past chair of the Department of Biochemistry at Maastricht University and past chair of the Netherlands Society on Thrombosis and Haemostasis (NVTH). He is actively involved with the International Society on Thrombosis and Haemostasis (ISTH) and is a co-founder and organiser of the European Congress on Thrombosis and Haemostasis (ECTH). He is elected a member of the Royal Netherlands Society of Sciences and Humanities.
Dr Hackeng’s research programme investigates the role of blood coagulation proteins in thrombosis and cardiovascular disease, with an emphasis on anticoagulant regulatory pathways and the regulation of thrombin formation. Using a multidisciplinary approach, the programme employs structure-function analysis of coagulation proteins and the development of clinical assays to screen for functional impairments in patients with thrombosis. Additionally, his research includes chemical protein synthesis for applications in thrombosis and haemostasis, cancer, targeted molecular imaging, and synthetic vaccines, utilising technologies such as SPPS, native chemical ligation, and multimodal constructs for advanced molecular imaging and therapeutic applications.
OC 07.6 - Components of prothrombinase
Saturday, June 22, 2024
13:00 – 14:15 ICT
Saturday, June 22, 2024
13:15 – 13:30 ICT
Sunday, June 23, 2024
13:45 – 14:45 ICT
MC 10.1 - How do natural anticoagulants harness coagulation initiation and thrombosis?
Sunday, June 23, 2024
18:45 – 19:30 ICT
SOA 13.4 - New aspects of natural anticoagulants
Monday, June 24, 2024
08:00 – 09:15 ICT
OC 57.1 - Intrinsic activated thrombin generation for efficacy and monitoring of emicizumab
Tuesday, June 25, 2024
09:30 – 09:45 ICT
PB1080 - From clotting to calcification: Gla-domains as guardians of vascular remodeling
Tuesday, June 25, 2024
13:45 – 14:45 ICT
Tuesday, June 25, 2024
13:45 – 14:45 ICT
Wednesday, June 26, 2024
11:00 – 11:15 ICT